22 January 2021 (Friday) - Anti-Kp(a)

I had a rather fraught early shift today… in retrospect it wasn’t that busy, but having had a quiet one yesterday I had been hoping for more of the same. But within an hour or so of starting work I had detected an atypical blood group antibody and had identified it.
Anti-Kp(a) is rather obscure as antibodies go… with only two per cent of the population (at best) carrying the antigen it can be a challenge for those who produce antibody panels to be able to include it in their repertoire. I must admit I can’t remember having identified one myself before.

Directed at an antigen of the Kell blood group system, anti-Kp(a) can cause both haemolytic blood transfusion reactions and haemolytic disease of the foetus and newborn. Rather than copying and pasting (which would fool no one, here’s a few references…


 and loads more can be found in less than thirty seconds with a search on Google.
I learned something today…

21 January 2021 (Thursday) - Transfusion News Update


The nice people at Transfusion News sent their update today. D-genotyping, more about the use of convalescent plasma (there’s a lot of contradictory stuff being said about this)… all good stuff.

RHD Genotyping in Transfusion Practice Could Identify Novel RHD Alleles and Conserve D-negative Blood

January 20, 2021
Partial D phenotypes (with altered D epitopes) and weak D phenotypes (with a reduced number of D antigens present on RBCs) are difficult to distinguish based on serology alone. Thus, genotyping the RHD locus is recommended to limit the risk of alloimmunization and to avoid unnecessary use of RhIG and D- blood. [Read More]


Early Convalescent Plasma Therapy Helps Prevent Severe COVID-19

January 12, 2021
COVID-19 convalescent plasma administered late in the course of disease has not shown clear benefits, but some studies suggest that early transfusion may be efficacious. In order to determine if convalescent plasma administered soon after infection may help to prevent severe disease in older patients, researchers in Argentina randomized 160 patients aged 65 or older to receive either convalescent plasma (N=80) or placebo (N=80) within 72 hours of symptom onset. [Read More]


21 January 2021 (Thursday) - Transfusion Evidence Alert Update

The nice people at the Transfusion Evidence Alert sent their update today. Use of blood products, post-operative anemia… all good stuff.


Individualized, Intraoperative Dosing of Fibrinogen Concentrate for the Prevention of Bleeding in Neonatal and Infant Cardiac Surgery Using Cardiopulmonary Bypass (FIBCON): A Phase 1b/2a Randomized Controlled Trial.
Siemens, K., et al. (2020). Circulation: Cardiovascular Interventions.
PICO Summary available



Prophylactic use of tranexamic acid for decreasing the blood loss in elective cesarean section: A placebo-controlled randomized clinical trial.
Naeiji, N., et al. (2020). Journal of Gynecology Obstetrics and Human Reproduction. 

Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial).
Green, L., et al. (2020). Anaesthesia. [Record in progress]

The Impact of Preoperative Intravenous Iron Therapy on Perioperative Outcomes in Cardiac Surgery: A Systematic Review.
Tankard, K. A., et al. (2020). Journal of Hematology.

Quality assessment of red blood cell suspensions derived from pathogen-reduced whole blood.
Kumukova, I., et al. (2020). Vox Sanguinis. [Record in progress]

Techniques for blood loss estimation in major non-cardiac surgery: a systematic review and meta-analysis.
Tran, A., et al. (2020). Journal Canadien D'Anesthesie. [Record in progress]

Impact and Outcomes of Postoperative Anaemia in Colorectal Cancer Patients: A Systematic Review.
Moncur, A., et al. (2020). Colorectal Disease [Record in progress]

Blood Donation Practice and Associated Factors in Ethiopia: A Systematic Review and Meta-analysis.
Getie, A., et al. (2020). BioMed Research International.